Cargando…

Metastatic phenotype in CWR22 prostate cancer xenograft following castration

BACKGROUND: CWR22 is a human xenograft model of primary prostate cancer (PCa) that is often utilized to study castration recurrent (CR) PCa. CWR22 recapitulates clinical response to androgen deprivation therapy (ADT), in that tumors regress in response to castration, but can recur after a period of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seedhouse, Steven J., Affronti, Hayley C., Karasik, Ellen, Gillard, Bryan M., Azabdaftari, Gissou, Smiraglia, Dominic J., Foster, Barbara A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745026/ https://www.ncbi.nlm.nih.gov/pubmed/26642837 http://dx.doi.org/10.1002/pros.23127

Ejemplares similares

Src controls castration recurrence of CWR22 prostate cancer xenografts
por: Su, Bing, et al.
Publicado: (2013)

Dietary folate levels alter the kinetics and molecular mechanism of prostate cancer recurrence in the CWR22 model
por: Affronti, Hayley C., et al.
Publicado: (2017)

The essential role of methylthioadenosine phosphorylase in prostate cancer
por: Bistulfi, Gaia, et al.
Publicado: (2016)

Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy
por: Affronti, Hayley C., et al.
Publicado: (2020)

LSD1 dual function in mediating epigenetic corruption of the vitamin D signaling in prostate cancer
por: Battaglia, Sebastiano, et al.
Publicado: (2017)

Dynamic patterns of DNA methylation in the normal prostate epithelial differentiation program are targets of aberrant methylation in prostate cancer
por: Long, Mark D., et al.
Publicado: (2021)

Knockout of Akt1/2 suppresses the metastasis of human prostate cancer cells CWR22rv1 in vitro and in vivo
por: Su, Bing, et al.
Publicado: (2020)

Early Growth Inhibition Is Followed by Increased Metastatic Disease with Vitamin D (Calcitriol) Treatment in the TRAMP Model of Prostate Cancer
por: Ajibade, Adebusola Alagbala, et al.
Publicado: (2014)

Clinicopathologic characterization of intradiverticular carcinoma of urinary bladder - a study of 22 cases from a single cancer center
por: Zhong, Hua, et al.
Publicado: (2014)

Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis
por: Ellis, Leigh, et al.
Publicado: (2014)

Human Prostate Side Population Cells Demonstrate Stem Cell Properties in Recombination with Urogenital Sinus Mesenchyme
por: Foster, Barbara A., et al.
Publicado: (2013)

Aldehyde dehydrogenase and ATP binding cassette transporter G2 (ABCG2) functional assays isolate different populations of prostate stem cells where ABCG2 function selects for cells with increased stem cell activity
por: Gangavarapu, Kalyan J, et al.
Publicado: (2013)

Novel chloroacetamido compound CWR-J02 is an anti-inflammatory glutaredoxin-1 inhibitor
por: Gorelenkova Miller, Olga, et al.
Publicado: (2017)

Novel galeterone analogs act independently of AR and AR-V7 for the activation of the unfolded protein response and induction of apoptosis in the CWR22Rv1 prostate cancer cell model
por: McCarty, David J., et al.
Publicado: (2017)

Gene Expression in Single Cells Isolated from the CWR-R1 Prostate Cancer Cell Line and Human Prostate Tissue Based on the Side Population Phenotype
por: Gangavarapu, Kalyan J, et al.
Publicado: (2016)

Inhibition of WHSC1 Allows for Reprogramming of the Immune Compartment in Prostate Cancer
por: Want, Muzamil Y., et al.
Publicado: (2021)

JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
por: Rosario, Spencer R., et al.
Publicado: (2023)

The Longitudinal Force Measurement of CWR Tracks with Hetero-Cladding FBG Sensors: A Proof of Concept
por: Shao, Li-Yang, et al.
Publicado: (2016)

A moonlighting function of a chitin polysaccharide monooxygenase, CWR-1, in Neurospora crassa allorecognition
por: Detomasi, Tyler C, et al.
Publicado: (2022)

Aryl hydrocarbon receptor is a tumor promoter in MYCN-amplified neuroblastoma cells through suppression of differentiation
por: Chaudhry, Kanita A., et al.
Publicado: (2023)

Establishment and Characterization of a Highly Tumorigenic African American Prostate Cancer Cell Line, E006AA-hT
por: Koochekpour, Shahriar, et al.
Publicado: (2014)

Draft Genome Sequence of Verrucosispora sp. Strain CWR15, Isolated from a Gulf of Mexico Sponge
por: Kennedy, Sarah J., et al.
Publicado: (2020)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Effect of Random Lateral Ballast Resistance on Force-Deformation Characteristics of CWR with a Small-Radius Curve
por: Wang, Huan, et al.
Publicado: (2023)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling
por: Van Hemelryk, Annelies, et al.
Publicado: (2022)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
por: Zaitsu, Masayoshi, et al.
Publicado: (2012)

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
por: Scott, Lesley J.
Publicado: (2020)

Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
por: Pollard, Matthew E., et al.
Publicado: (2017)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
por: Markowski, Mark C, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fvinc3dm663gl53p3j8ejnsh1l